Role of C5 activation products in sepsis

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 2395-2402

  Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

C5a; C5a receptors; Cytokines; Polymicrobial sepsis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CHEMOKINE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5L2 RECEPTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; ENDOTOXIN; FAS ANTIGEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; G PROTEIN COUPLED RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN G ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NEUTRALIZING ANTIBODY; RAF PROTEIN; RAS PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR IIA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CARDIOMYOPATHY; CHEMOTAXIS; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; IN VIVO STUDY; INNATE IMMUNITY; LETHALITY; LYMPHOID CELL; MACROPHAGE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PLASMA CELL GRANULOMA; RESPIRATORY BURST; REVIEW; SEPSIS; UPREGULATION;

ANIMALS; APOPTOSIS; COMPLEMENT ACTIVATION; COMPLEMENT C5A; HUMANS; IMMUNITY, INNATE; MODELS, IMMUNOLOGICAL; MULTIPLE ORGAN FAILURE; RECEPTOR, ANAPHYLATOXIN C5A; SEPSIS;

EID: 78650289203     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.216     Document Type: Review

References (39)

1. Dombrovskiy, V.Y., Martin, A.A., Sunderram, J., and Paz, H.L. (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35(5), 1244-1250. (Pubitemid 46642649)
2. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M.R. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29(7), 1303-1310.
3. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., and Fisher, C.J., Jr. (2001) Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344(10), 699-709.
4. Huber-Lang, M., Younkin, E.M., Sarma, J.V., Riedemann, N., McGuire, S.R., Lu, K.T., Kunkel, R., Younger, J.G., Zetoune, F.S., and Ward, P.A. (2002) Generation of C5a by phagocytic cells. Am. J. Pathol. 161(5), 1849-1859.
5. Huber-Lang, M., Sarma, J.V., Zetoune, F.S., Rittirsch, D., Neff, T.A., McGuire, S.R., Lambris, J.D., Warner, R.L., Flierl, M.A., Hoesel, L.M., Gebhard, F., Younger, J.G., Drouin, S.M., Wetsel, R.A., and Ward, P.A. (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12(6), 682-687.
6. Guo, R.F. and Ward, P.A. (2005) Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821-852.
7. Otto, M., Hawlisch, H., Monk, P.N., Müller, M., Klos, A., Karp, C.L., and Köhl, J. (2004) C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J. Biol. Chem. 279(1), 142-151.
8. Guo, R.F. and Ward, P.A. (2002) Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. Free Radic. Biol. Med. 33(3), 303-310.
9. Dirksen, M.T., Laarman, G.J., Simoons, M.L., and Duncker, D.J. (2007) Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc. Res. 74(3), 343-355.
10. Lee, H., Whitfeld, P.L., and Mackay, C.R. (2008) Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol. Cell Biol. 86(2), 153-160.
11. Okinaga, S., Slattery, D., Humbles, A., Zsengeller, Z., Morteau, O., Kinrade, M.B., Brodbeck, R.M., Krause, J.E., Choe, H.R., Gerard, N.P., and Gerard, C. (2003) C5L2, a nonsignaling C5a binding protein. Biochemistry 42(31), 9406-9415. (Pubitemid 36959248)
12. Kalant, D., MacLaren, R., Cui, W., Samanta, R., Monk, P.N., Laporte, S.A., and Cianflone, K. (2005) C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 280(25), 23936-23944.
13. Chen, N.J., Mirtsos, C., Suh, D., Lu, Y.C., Lin, W.J., McKerlie, C., Lee, T., Baribault, H., Tian, H., and Yeh, W.C. (2007) C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446(7132), 203-207. (Pubitemid 46398661)
14. Gerard, N.P., Lu, B., Liu, P., Craig, S., Fujiwara, Y., Okinaga, S., and Gerard, C. (2005) An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 280(48), 39677-39680. (Pubitemid 41779098)
15. Johswich, K., Martin, M., Thalmann, J., Rheinheimer, C., Monk, P.N., and Klos, A. (2006) Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J. Biol. Chem. 281(51), 39088-39095.
16. Scola, A.M., Johswich, K.O., Morgan, B.P., Klos, A., and Monk, P.N. (2009) The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol. Immunol. 46(6), 1149-1162.
17. Gao, H., Neff, T.A., Guo, R.F., Speyer, C.L., Sarma, J.V., Tomlins, S., Man, Y., Riedemann, N.C., Hoesel, L.M., Younkin, E., Zetoune, F.S., and Ward, P.A. (2005) Evidence for a functional role of the second C5a receptor C5L2. FASEB J. 19(8), 1003-1005. (Pubitemid 40827732)
18. Bamberg, C.E., Mackay, C.R., Lee, H., Zahra, D., Jackson, J., Lim, Y.S., Whitfeld, P.L., Craig, S., Corsini, E., Lu, B., Gerard, C., and Gerard, N.P. (2010) The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol. Chem. 285(10), 7633-7644.
19. Stevens, J.H., O'Hanley, P., Shapiro, J.M., Mihm, F.G., Satoh, P.S., Collins, J.A., and Raffin, T.A. (1986) Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77(6), 1812-1816.
20. Rittirsch, D., Flierl, M.A., Nadeau, B.A., Day, D.E., Huber-Lang, M., Mackay, C.R., Zetoune, F.S., Gerard, N.P., Cianflone, K., Köhl, J., Gerard, C., Sarma, J.V., and Ward, P.A. (2008) Functional roles for C5a receptors in sepsis. Nat. Med. 14(5), 551-557.
21. Czermak, B.J., Sarma, V., Pierson, C.L., Warner, R.L., Huber-Lang, M., Bless, N.M., Schmal, H., Friedl, H.P., and Ward, P.A. (1999) Protective effects of C5a blockade in sepsis. Nat. Med. 5(7), 788-792.
22. Huber-Lang, M.S., Sarma, J.V., McGuire, S.R., Lu, K.T., Guo, R.F., Padgaonkar, V.A., Younkin, E.M., Laudes, I.J., Riedemann, N.C., Younger, J.G., and Ward, P.A. (2001) Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J. 15(3), 568-570.
23. Solomkin, J.S., Jenkins, M.K., Nelson, R.D., Chenoweth, D., and Simmons, R.L. (1981) Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery 90(2), 319-327.
24. Huber-Lang, M.S., Younkin, E.M., Sarma, J.V., McGuire, S.R., Lu, K.T., Guo, R.F., Padgaonkar, V.A., Curnutte, J.T., Erickson, R., and Ward, P.A. (2002) Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169(6), 3223-3231. (Pubitemid 35013169)
25. Guo, R.F., Riedemann, N.C., Bernacki, K.D., Sarma, V.J., Laudes, I.J., Reuben, J.S., Younkin, E.M., Neff, T.A., Paulauskis, J.D., Zetoune, F.S., and Ward, P.A. (2003) Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J. 17(13), 1889-1891.
26. Riedemann, N.C., Guo, R.F., Neff, T.A., Laudes, I.J., Keller, K.A., Sarma, V.J., Markiewski, M.M., Mastellos, D., Strey, C.W., Pierson, C.L., Lambris, J.D., Zetoune, F.S., and Ward, P.A. (2002) Increased C5a receptor expression in sepsis. J. Clin. Invest. 110(1), 101-108.
27. Riedemann, N.C., Guo, R.F., Laudes, I.J., Keller, K., Sarma, V.J., Padgaonkar, V., Zetoune, F.S., and Ward, P.A. (2002) C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 16(8), 887-888. (Pubitemid 34743470)
28. Yang, H., Wang, H., Czura, C.J., and Tracey, K.J. (2005) The cytokine activity of HMGB1. J. Leukoc. Biol. 78(1), 1-8.
29. Kalant, D., Cain, S.A., Maslowska, M., Sniderman, A.D., Cianflone, K., and Monk, P.N. (2003) The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J. Biol. Chem. 278(13), 11123-11129. Erratum in: (2004) J. Biol. Chem. 279(1), 820.
30. Flierl, M.A., Rittirsch, D., Nadeau, B.A., Day, D.E., Zetoune, F.S., Sarma, J.V., Huber-Lang, M.S., and Ward, P.A. (2008) Functions of the complement components C3 and C5 during sepsis. FASEB J. 22(10), 3483-3490.
31. Prodeus, A.P., Zhou, X., Maurer, M., Galli, S.J., and Carroll, M.C. (1997) Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 390(6656), 172-175. (Pubitemid 27507986)
32. Parker, C.J., Kar, S., and Kirkpatrick, P. (2007) Eculizumab. Nat. Rev. Drug Discov. 6(7), 515-516.
33. Buras, J.A., Rice, L., Orlow, D., Pavlides, S., Reenstra, W.R., Ceonzo, K., and Stahl, G.L. (2004) Inhibition of C5 or absence of C6 protects from sepsis mortality. Immunobiology 209(8), 629-635. (Pubitemid 40057724)
34. Hotchkiss, R.S. and Nicholson, D.W. (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6(11), 813-822.
35. Ward, P.A. (2008) Sepsis, apoptosis and complement. Biochem. Pharmacol. 76(11), 1383-1388.
36. Flierl, M.A., Rittirsch, D., Chen, A.J., Nadeau, B.A., Day, D.E., Sarma, J.V., Huber-Lang, M.S., and Ward, P.A. (2008) The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS One 3(7), e2560.
37. Niederbichler, A.D., Hoesel, L.M., Westfall, M.V., Gao, H., Ipaktchi, K.R., Sun, L., Zetoune, F.S., Su, G.L., Arbabi, S., Sarma, J.V., Wang, S.C., Hemmila, M.R., and Ward, P.A. (2006) An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J. Exp. Med. 203(1), 53-61.
38. Joulin, O., Petillot, P., Labalette, M., Lancel, S., and Neviere, R. (2007) Cytokine profile of human septic shock serum inducing cardiomyocyte contractile dysfunction. Physiol. Res. 56, 291-297.
39. Cain, B.S., Meldrum, D.R., Dinarello, C.A., Meng, X., Joo, K.S., Banerjee, A., and Harken, A.H. (1999) Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit. Care Med. 27, 1309-1318.